Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S19-1035
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
- Modality
- Small Molecules
01
Overview
S19-1035 is a potent and highly selective small molecule inhibitor of aldo-keto reductase 1C3 (AKR1C3). AKR1C3 is an enzyme overexpressed in various hormone-related malignancies, including breast and prostate cancers, where it plays a critical role in tumor progression and the development of resistance to anthracycline-based chemotherapy. By specifically inhibiting AKR1C3, S19-1035 prevents the metabolic inactivation of drugs like doxorubicin, thereby restoring chemosensitivity in resistant cancer cells. In preclinical studies, S19-1035 demonstrated an IC50 of 3.04 nM and over 3000-fold selectivity against other AKR1C isoforms, making it a promising adjuvant candidate for breast cancer treatment.
02
Targets
AKR1C3 (Aldo-keto reductase family 1 member C3)
Beyond the preview
Go deeper on S19-1035.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S19-1035.